| Literature DB >> 30911406 |
N A Mobbs1,2, J Ditai1,3, J Abeso3,4, E B Faragher5, E D Carrol6, M Gladstone7, A Medina-Lara8, P Olupot-Olupot9, A D Weeks1.
Abstract
BACKGROUND: Due to their immature immune system, neonates are at high risk of infection. This vulnerability when combined with limited resources and health education in developing countries can lead to sepsis, resulting in high global neonatal mortality rates. Many of these deaths are preventable. The BabyGel pilot trial tested the feasibility of conducting the main randomised trial, with the provision of alcohol handgel to postpartum mothers for prevention of neonatal infective morbidity in the rural community. This secondary analysis sought to evaluate the methods of detecting infections in babies up to 3 months of age.Entities:
Keywords: Antibiotics; Diagnosis; Hand hygiene; Infection; Neonate; Paediatrics; Primary outcome; Sepsis; Uganda
Year: 2019 PMID: 30911406 PMCID: PMC6415494 DOI: 10.1186/s40814-019-0428-3
Source DB: PubMed Journal: Pilot Feasibility Stud ISSN: 2055-5784
Fig. 1The IMCI screening criteria for infection
Demographics of study participants
| Total participants | 103 |
| Age* | |
| 15–20 | 25 (24.3) |
| 21–30 | 56 (54.4) |
| 31–40 | 21 (20.4) |
| Mean age | 24.9 |
| Marital status | |
| Single | 22 (21.4) |
| Married | 80 (77.7) |
| Divorced/separated | 0 |
| Widowed | 1 (1.0) |
| Highest level of education | |
| No formal education | 3 (2.9) |
| Did not complete primary education | 52 (50.5) |
| Completed primary (PLE) | 32 (31.1) |
| Completed ordinary or advanced level (UCE/UACE) | 14 (13.6) |
| Completed diploma or degree | 2 (1.9) |
| Primary occupation | |
| Peasant farmer, no paid employment, or housewife | 95 (92.2) |
| Student | 3 (2.9) |
| Business woman | 2 (1.9) |
| Professional | 1 (1.0) |
| Others | 2 (1.9) |
*Data missing on 1 woman
Fig. 2A flow diagram to illustrate the study results
Fig. 3Venn diagram indicating the various sources by which presumed infection was identified in participants
Results of the study for all participants
|
| % (95% CI) | |
|---|---|---|
| Total maternal recruits | 103 | |
| Withdrawals | 2 | |
| Stillbirths | 3 | |
| Neonatal deaths | 2 | |
| Total infants screened + followed up* | 99 | |
| Any evidence of infection | 55 | 55.6 (45.2:65.5) |
| Positive screen | ||
| Day 1 | 8 | 8.1 (3.6:15.3) |
| Interim | 27 | 27.3 (18.8:37.1) |
| Day 90 | 3 | 3.0 (0.6:8.6) |
| Day 1 and/or interim and/or day 90 | 30 | 30.3 (21.5:40.4) |
| Clinical diagnosis of infection (from clinical notes) | 19 | 19.2 (12.0:28.3) |
| Oomphalitis | 1 | 1.0 (< 0.1:5.5) |
| Pneumonia | 2 | 2.0 (0.2:7.1) |
| Diarrhoea | 1 | 1.0 (< 0.1:5.5) |
| Neonatal septicaemia | 6 | 6.1 (2.3:12.7) |
| Upper respiratory tract infection | 3 | 3.0 (0.6:8.6) |
| Skin pustules/infection | 3 | 3.0 (0.6:8.6) |
| Evidence from all three sources | 12 | 12.1 (6.4:20.2) |
| Unspecified source | 3 | 3.0 (0.6:8.6) |
| Microbiological evidence | 5 | 5.1 (1.7:11.4) |
| Maternally reported infection | 45 | 45.5 (35.4:55.8) |
| Received antibiotics | 22 | 22.2 (14.5:31.7) |
| Infants receiving antimalarial medication | 8 | 8.1 (3.6:15.3) |
CI confidence interval
*Includes 1 set of twins, 1 neonatal death (screened at day 1), and 1 withdrawal (screened at day 1)
Criteria indicating presumed infection in infants (based on IMCI screening forms)
| Day | Difficulty feeding | Convulsions | Moving only when stimulated /not at all | Chest wall indrawing | Fast respiratory rate | High axillary temperature | Low axillary temperature |
|---|---|---|---|---|---|---|---|
| 1 | 5 | 0 | 0 | 0 | 0 | 4 | 0 |
| 90 | 1 | 1 | 1 | 1 | 0 | 2 | 0 |
| Interim (day 2–89) | 9 | 3 | 2 | 5 | 19 | 11 | 1 |
| Totals | 15 | 4 | 3 | 6 | 19 | 17 | 1 |
Outcome for culture samples obtained
| Organisms | ||
|---|---|---|
| Total samples taken | 16 | |
| Blood samples | 10 (62.5) | |
| Pus swab | 2 (12.5) | |
| Stool sample | 4 (25.0) | |
| Cerebrospinal fluid | 0 | |
| Total positive samples | 5 (31.3) | |
| Positive blood cultures | 3 (18.8) | |
| Positive pus swabs | 1 (6.3) | |
| Positive stool samples | 1 (6.3) | |
| Cerebrospinal fluid | 0 |
A table indicating antibiotic use in all infants with suspected infection
|
| % | |
|---|---|---|
| Total participants with infection | 55 | 100 |
| Total antibiotic exposure | 22 | 40.0 (27.0:54.1) |
| Sources of evidence for antibiotic use | ||
| Clinical notes | 17 | 30.9 (19.1:44.8) |
| Direct question addressing use of any medication on IMCI form | 3 | 5.5 (1.1:15.1) |
| Comments on antibiotic use (free text) | 19 | 34.5 (22.2:48.6) |
| Total antibiotic exposures | 52* | 100 |
| Named antibiotic | ||
| Amoxicillin | 8 | 15.4 (6.9:28.1) |
| Ceftriaxone | 10 | 19.2 (9.6:32.5) |
| Gentamycin | 7 | 13.5 (5.6:25.8) |
| Metronidazole | 3 | 5.8 (1.2:15.9) |
| Ampiclox | 4 | 7.7 (2.1:18.5) |
| Nalidixic acid | 1 | 1.9 (0.1:10.3) |
| Ampicillin | 4 | 7.7 (2.1:18.5) |
| Cloxacillin | 2 | 3.8 (0.5:13.2) |
| Benzyl penicillin | 2 | 3.8 (0.5:13.2) |
| Co-trimoxazole | 6 | 11.5 (4.4:23.4) |
| Neomycin | 1 | 1.9 (0.1:10.3) |
| Amikacin | 1 | 1.9 (0.1:10.3) |
| Mupirocin | 1 | 1.9 (0.1:10.3) |
| Tetracycline | 1 | 1.9 (0.1:10.3) |
| Erythromycin | 1 | 1.9 (0.1:10.3) |
*Many babies had more than 1 antibiotic